Anteris Technologies Ltd (ASX:AVR) (FRA:DDF) will host a key opinion leader symposium on the use of transcatheter aortic valve replacement (TAVR) on July 21, 2020, at 1:00am AEST (July 20 at 11:00 am USA EDT).
The company will update on its TAVR research & development program, as well as on the ongoing first-in-human trial of its ADAPT® 3D single-piece aortic valve for Surgical Aortic Valve Replacement (SAVR) procedures.
The symposium, entitled 'Next Generation Technologies for the era of TAVR in Younger Low-Risk Patients with Aortic Stenosis', will provide investors and analysts with a comprehensive profile of current trends in the use of TAVR and the future of this technology to treat younger, low-risk patients with aortic stenosis.
It will address how current TAVR solutions are suitable for this newly approved patient demographic, what challenges they have, and what are the leading next-generation technologies that are in development.
Key opinion leaders
The forum will be moderated by Matt Miksic, senior analyst at Credit Suisse, and will feature the following key opinion leaders:
➢ Dr Samir Kapadia, MD (Cleveland Clinic, Cleveland, Ohio)
➢ Dr Michael Reardon, MD (Houston Methodist, Houston, Texas)
➢ Dr Paul Sorajja, MD (Minneapolis Heart Institute Foundation, Minneapolis, Minnesota)